The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Subscribe To Our Newsletter & Stay Updated
